** Shares of biopharma firm CorMedix CRMD.O rise 3.6% to $9.83 premarket
** Leerink Partners starts coverage of CRMD with "outperform" rating and PT of $18, which represents 89.6% upside to stock's last close
** Brokerage says co's medical device, DefenCath, is "significant advancement" in catheter-related bloodstream infection prevention, reducing infection rates by up to 70%
** DefenCath is used to prevent infections in catheters, a thin tube used in medical procedures, for patients with kidney failure undergoing hemodialysis
** Brokerage expects DefenCath to reach $370 mln in sales by 2028
** Notes co has "solid commercial execution" and has partnered with 60% of U.S. dialysis clinics, which will drive "significant volume growth potential for DefenCath"
** Stock more than doubled in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.